author-photo

Lukas C. Amler

Genentech
German Cancer Research Center

144

Papers

8969

Citations

Citation Trend

Filter By

Papers (109) Sort By

Journal Conference Others

Absence of PD-L1 expression on tumor cells in the context of an activated immune infiltrate may indicate impaired IFNγ signaling in non-small cell lung cancer

2019 PLOS ONE
Show All
- Source
- Cite
- Save
Citations (6)
Abstract A41: Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC

2018 Cancer immunology research
Show All
- Source
- Cite
- Save
Citations (0)
A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer types

2018
Show All
- Source
- Cite
- Save
Citations (53)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab

2018 Nature Medicine
Show All
- Source
- Cite
- Save
Citations (532)
Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK)

2018 Pneumologie
Show All
- Source
- Cite
- Save
Citations (4)
Association of high tissue TMB and atezolizumab efficacy across multiple tumor types.

2018 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (32)
Abstract A41: Analytic validation and clinical feasibility of a next-generation sequencing assay to assess tumor mutational burden from blood (bTMB) as a biomarker for anti-PD-L1 response in NSCLC

2018 Clinical research
Show All
- Source
- Cite
- Save
Citations (0)
Biomarker analysis of the NeoSphere study: Pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer

2017 Breast Cancer Research
Show All
- Source
- Cite
- Save
Citations (54)
1295OBlood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)

2017 Annals of Oncology
Show All
- Source
- Cite
- Save
Citations (58)
Abstract 1750: Analysis of non-metastatic HCC patient tumors revealed the significance of cell cycle regulation and tumor immunity in association with overall survival and identified clinically relevant druggable targets

2017 Cancer Research
Show All
- Source
- Cite
- Save
Citations (0)